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Summary
 
Anti–double-stranded DNA (dsDNA) antibodies are the serologic abnormality characteristi-
cally associated with systemic lupus erythematosus (SLE) and may play an important role in dis-
ease pathogenesis. Although the anti-dsDNA antibodies present in SLE are indicative of an an-
tigen-driven response, the antigen has not been conclusively identified.
By screening a phage peptide display library, we demonstrated previously that the decapep-
tide DWEYSVWLSN is specifically bound by the pathogenic murine IgG2b anti-dsDNA anti-
body R4A. To investigate the possibility that a protein antigen might trigger lupus-like au-
toimmunity, we immunized BALB/c mice with DWEYSVWLSN in adjuvant. Mice developed
significant titers of IgG anti-dsDNA antibodies 2–3 wk after the initial immunization. Immu-
nized mice also developed antibodies against some other lupus autoantigens, and immunoglob-
ulin deposition was present in renal glomeruli at 49 d. Although an immune response to pep-
tide and dsDNA was evident in BALB/c mice, there was little response in other inbred strains.
This study demonstrates that lupus-like anti-dsDNA reactivity can be generated in nonauto-
immune mice by immunization with a peptide antigen. Peptide-induced autoimmunity may
prove useful in understanding the spreading of antigenic specificities targeted in SLE. How-
ever, most importantly, the demonstration that a peptide antigen can initiate a SLE-like im-
mune response opens a new chapter on the potential antigenic stimuli that might trigger SLE.
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nti–double-stranded DNA (dsDNA)
 
1
 
 autoantibodies
are a diagnostic feature of SLE. Many analyses of these
antibodies have shown them to have the characteristics of
antibodies arising in an antigen-driven response (1–3). Lu-
pus-associated anti-dsDNA antibodies display high affinity
for dsDNA, have undergone H chain class switching to
IgG, and display somatic mutations in their variable region
gene segments. Nevertheless, it remains uncertain what an-
tigen triggers the production of these antibodies. Mamma-
lian dsDNA is poorly immunogenic (4). Although some
bacterial DNAs appear to be immunogenic in normal
mouse strains, they do not elicit production of antibodies
that cross-react with eukaryotic DNA (5, 6). Therefore, it
remains unclear if DNA or nucleosomes induce anti-DNA
antibodies in lupus-prone mice or if anti-dsDNA antibod-
ies are made in response to some other antigen, either self
or foreign. Specifically, anti-DNA antibodies cross-react
with bacterial antigens (7, 8), and bacterial polysaccharide
can trigger production of anti-DNA antibodies (9).
We have previously described R4A, a murine IgG2b
anti-dsDNA mAb that deposits in glomeruli of nonautoim-
mune mouse strains (10). In an attempt to understand the
fine specificity of the R4A antibody, we screened a phage
decapeptide display library with R4A, and have reported
that the peptide DWEYSVWLSN and the smaller peptide
DWEYS that represents a consensus motif found in several
peptides recognized by R4A, are bound by the antibody.
DWEYS in either the L or the D form can inhibit the
binding of R4A to dsDNA, and when administered
 
 
 
in vivo
to mice in the D-peptide configuration, can inhibit kidney
deposition of R4A (11)
 
.
 
To test a possible role of protein antigens in the induc-
tion of anti-dsDNA antibodies, we immunized BALB/c
 
1
 
Abbreviations used in this paper:
 
 ANA, antinuclear antibody; dsDNA, dou-
ble-stranded DNA; GXM, glucoronoxylomannan; MAP, multiple anti-
genic peptide; RNP, ribonucleoprotein.
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mice and other nonautoimmune mouse strains with the
R4A-specific peptide DWEYSVWLSN configured as a
multimer on a multiple antigenic peptide (MAP) backbone
(12, 13). Immunized BALB/c mice developed anti-dsDNA
antibodies and some other autoantibodies, as well as glom-
erular immunoglobulin deposition suggestive of lupus ne-
phritis.
 
Materials and Methods
 
Derivation of R4A and DWEYS.
 
The derivation of the anti-
dsDNA antibody R4A (10) and the peptide DWEYSVWLSN
have been described previously (11). In brief, R4A is a murine
IgG2b antibody isolated from a nonautoimmune BALB/c mouse,
encoded by an unmutated S107 V11 germline gene and an un-
mutated germline V
 
k
 
1 L chain gene. The R4A antibody binds
dsDNA and deposits in glomeruli of SCID mice.
The DWEYSVWLSN peptide was identified by screening a
phage decapeptide display library with R4A. After three rounds
of selection, phage clones were amplified, and the oligonucle-
otide inserts were sequenced. The consensus peptide motif for
the R4A-selected phage clones was D/E-W-D/E-Y-S/G. The
soluble peptide DWEYS inhibited binding of R4A to dsDNA.
The D configuration of the DWEYS peptide markedly inhibited
R4A deposition in glomeruli of SCID mice in vivo (11).
 
Immunization.
 
4–6-wk-old female nonautoimmune BALB/cJ
mice (The Jackson Laboratory, Bar Harbor, ME) were used for
immunizations. DWEYSVWLSN was prepared for immuniza-
tion on an eight-branched lysine backbone (MAP
 
Ô
 
; Applied
Biosystems, Foster City, CA; peptide on MAP from Research
Genetics, Huntsville, AL; references 12 and 13). Mice were im-
munized subcutaneously with 100 
 
m
 
g of MAP–peptide in CFA
H37 Ra (Difco Laboratories, Detroit, MI) on day 0, followed by
subcutaneous booster injections of 100 
 
m
 
g of MAP–peptide in
IFA (Difco Laboratories) on days 
 
1
 
7 and 
 
1
 
14. Control mice
matched for strain, sex, and age were immunized with the MAP
backbone only (MAP core) in adjuvant using an identical sched-
ule. Serum was obtained on days 0, 
 
1
 
7, 
 
1
 
14, 
 
1
 
21, 
 
1
 
35, and
 
1
 
49. Mice were housed in the Albert Einstein College of Medi-
cine animal barrier facility.
 
Inbred Strains.
 
A/J, AKR/J, DBA/2, and C57BL/6 mice
were obtained from The Jackson Laboratory. CBA/Ca mice
were purchased from Harlan Sprague Dawley (Indianapolis, IN).
4–6-wk-old female mice were immunized in groups of five mice
using the protocol detailed above for BALB/c mice.
 
Antipeptide Antibody ELISA.
 
Amidated, acetylated DWEYSV-
WLSN was synthesized at the peptide synthesis facility of the Al-
bert Einstein College of Medicine. Peptide purity was 
 
$
 
90% as
assayed by HPLC. To assay for the presence of antipeptide anti-
bodies, peptide at 20 
 
m
 
g/ml in PBS was adsorbed to Falcon Pro-
Bind 96-well microtiter plates (Becton Dickinson, Lincoln Park,
NJ) at 4
 
8
 
C overnight. Plates were blocked with 3% FCS (Hy-
clone Laboratories, Logan, UT) in PBS for 1 h at 37
 
8
 
C and then
incubated with serum at a 1:500 dilution in PBS for 2 h at 37
 
8
 
C.
The plates were then washed five times with PBS-Tween, and al-
kaline phosphatase–conjugated goat anti–mouse IgG or IgM
(Southern Biotechnology Associates, Birmingham, AL) diluted
1:1,000 in 3% FCS/PBS was added for 1 h at 37
 
8
 
C, followed by
 
p
 
-nitrophenyl phosphate (alkaline phosphatase substrate) solution
(Sigma Chemical Co., St. Louis, MO). OD was monitored at
405 nm.
 
Anti-dsDNA ELISA.
 
Salmon sperm dsDNA (Calbiochem
Novabiochem, La Jolla, CA) was purified by filtration with a
0.45-
 
m
 
m filter (Millex HA; Millipore Corp., Bedford, MA).
Salmon sperm dsDNA, 100 
 
m
 
l per well at 100 
 
m
 
g/ml was ad-
sorbed to Immulon II 96-well microtiter plates (Dynatech Labo-
ratories Inc., Chantilly, VA), dried overnight at 37
 
8
 
C, and
blocked with 3% FCS in PBS for 1 h at 37
 
8
 
C. Serum at a 1:500
dilution in PBS was incubated for 2 h at 37
 
8
 
C, and the assay was
performed as described above. Specificity for dsDNA was con-
firmed using murine anti–single-stranded DNA mAbs (gifts from
Dr. G. Gilkeson, University of South Carolina, and Dr. J. Erikson,
University of Pennsylvania) that showed no binding in this assay
 
.
 
Isotype and IgG subclass analysis was performed as above, us-
ing the appropriate secondary alkaline phosphatase–linked anti-
bodies obtained from Southern Biotechnology Associates. For
analysis of S107 VH gene expression of the anti-dsDNA antibod-
ies, serum at 1:100 dilution was incubated on dsDNA-coated
plates, followed by supernatant from the TC54 cell line (rat anti–
mouse S107 V1 and V11; reference 14) for 2 h at 37
 
8
 
C. Alkaline
phosphatase–linked goat anti–rat IgG (H
 
1
 
L) antibody (Southern
Biotechnology Associates) was added for 1 h at 37
 
8
 
C, and the as-
say was then developed with substrate and read as above.
 
Millipore Filter Assay for Anti-dsDNA Antibodies.
 
The Millipore
filter assay for anti-dsDNA antibodies was performed as described
(15). In brief, double-stranded Lambda DNA (Boehringer Mann-
heim Corp., Indianapolis, IN) was labeled with P
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 using the Re-
diprime kit (Amersham Life Science, Little Chalfont, UK). Ra-
dioactive dsDNA was incubated with serum at a 1:5,000 dilution
for 1 h at 37
 
8
 
C and filtered through a 0.45-
 
m
 
m filter (Millipore
Corp.). The filters were washed with 1
 
3
 
 SSC, and retained ra-
dioactivity was counted on a scintillation counter
 
.
Isotype Quantitation.
 
Quantitation of IgG subclasses in the an-
tipeptide and anti-dsDNA responses was performed using stan-
dard curves for subclass concentration. Antipeptide and anti-
dsDNA ELISAs on serial dilutions of mouse serum starting from
1:100 were developed with alkaline phosphatase–linked antibod-
ies to mouse IgG subclasses (IgG1, IgG2a, IgG2b, and IgG3) from
Southern Biotechnology Associates. The Ig concentration was
calculated directly from a standard curve generated concurrently
using purified mouse myeloma proteins (MOPC 31C-IgG1,
 
k
 
;
UPC 10-IgG2a,
 
k
 
; MOPC 141-IgG2b,
 
k
 
; and FLOPC 21-IgG3,
 
k
 
;
Sigma Chemical Co.) and alkaline phosphatase–linked anti-IgG
subclass antibodies as above.
 
Nuclear Antigen ELISA.
 
Purified histone and cardiolipin were
obtained commercially. Histone (Boehringer Mannheim Corp.)
was adsorbed to Immulon II (Dynatech Laboratories, Inc.) 96-
well microtiter plates overnight at 4
 
8
 
C at a concentration of 10
 
m
 
g/ml (in PBS). Cardiolipin (Fluka Chemical Corp., Ronkonkoma,
NY) was adsorbed to Immulon II 96-well microtiter plates (Dy-
natech Laboratories Inc.) at room temperature overnight at a
concentration of 75 
 
m
 
g/ml in ethanol. The assays were then per-
formed as described above for measuring antipeptide antibodies.
 
Inhibition ELISAs.
 
Plates were coated with dsDNA or his-
tone as described above. 
 
l
 
-DWEYS at an initial concentration of
6.4 mM (5 mg/ml), was assessed for its ability to inhibit binding
of sera from peptide-immunized BALB/c mice to nuclear anti-
gens. Plates were blocked with 3% FCS in PBS for 1 h at 37
 
8
 
C,
and serial 1:2 dilutions of inhibitor (50 
 
m
 
l) were added to the an-
tigen-coated wells. Sera from day 
 
1
 
49 at 1:250 (50 
 
m
 
l; final con-
centration 1:500) was added to the inhibitor solution and then in-
cubated for 2 h at 37
 
8
 
C. The assay was then performed as
described above.
 
Antinuclear Antibodies by Immunofluorescence.
 
Antinuclear anti- 
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bodies (ANA) were assayed on Hep-2 cells according to the pro-
tocol supplied by the manufacturer (Immunoconcepts, Sacra-
mento, CA). Serial dilutions of serum beginning at 1:40 were
incubated on the slides for 30 min followed by a fluoresceinated
goat anti–mouse IgG antibody (Southern Biotechnology Associ-
ates) for 30 min at room temperature. Slides were rinsed, washed,
mounted with coverslips, and viewed with a fluorescence micro-
scope (Carl Zeiss, Inc., Thornwood, NY). Results were reported
as the last dilution at which fluorescence was clearly detectable.
 
Renal Deposition of Ig.
 
The technique for the assessment of
kidney Ig deposition has been reported previously (16). In brief,
one kidney from each animal was fixed in 10% formalin and em-
bedded in paraffin. 4-
 
m
 
m-thick sections were cut, deparaffinized,
rehydrated, blocked with 2% filtered horse serum in PBS in moist
chambers, and stained for 1 h with biotinylated goat anti–mouse
IgG (Vector Laboratories, Inc., Burlingame, CA) or each biotiny-
lated goat anti–mouse IgG subclass (IgG1, IgG2a, IgG2b, and
IgG3; Southern Biotechnology Associates) at a 1:800 dilution at
room temperature. Sections were washed, incubated for 45 min
with streptavidin-alkaline phosphatase, and developed with BCIP
and NBT (GIBCO BRL, Gaithersburg, MD). Color development
was stopped after 30 min by washing in distilled water. Coverslips
were mounted on the stained sections with cytosol mounting so-
lution (Aqua Polymount; Polysciences Inc., Warrington, PA). The
sections were then sealed and viewed with a Zeiss microscope.
 
Results
 
DWEYSVWLSN Induces ANA.
 
Immunization of BALB/c
mice with the octameric peptide MAP–DWEYSVWLSN
in CFA, followed by two booster injections of MAP–pep-
tide in IFA, resulted in production of antipeptide antibod-
ies. There was a small IgM antipeptide response in both
peptide-immunized mice and in mice immunized with
MAP core alone. The IgG antipeptide titer in MAP–pep-
tide-immunized mice rose by day 14 and continued to in-
crease until day 49 when the mice were killed (Fig. 1). The
IgG1 subclass dominated the IgG antipeptide response. Al-
though IgG2a, IgG2b, and IgG3 antipeptide antibodies were
also detectable, these were present at lower levels (Fig. 2).
The anti-DWEYSVWLSN response was specific: IgG anti-
body titers to phosphorylcholine, KLH, and lysozyme did
not increase significantly (Fig. 3).
 
Peptide Immunization Induces Anti-dsDNA Antibodies.
 
To
determine whether the peptide was a true mimotope of
dsDNA, we measured the anti-dsDNA antibody titer in
peptide-immunized mice. Although only a small increase
in the titer of IgM anti-dsDNA antibodies was found in
peptide-immunized mice compared with mice immunized
with
 
 
 
MAP core
 
 
 
(Fig. 4, 
 
left
 
), a marked rise in the IgG anti-
dsDNA antibody titer was observed (Fig. 4, 
 
right
 
). Dilution
studies demonstrated that the titer of IgG anti-dsDNA anti-
bodies in peptide-immunized mice at 3 mo of age was only
slightly lower than the titer in 6-mo-old nonimmunized
(NZB 
 
3
 
 NZW) F1 mice (Fig. 5). Spontaneously arising
anti-dsDNA antibodies from the lupus-prone (NZB 
 
3
 
NZW) F1 mouse are mostly of the IgG2a and IgG2b iso-
type (reference 17, and Fig. 6). In peptide-immunized mice,
the IgG1 isotype dominated the anti-dsDNA response (Fig.
6), although both IgG2a and IgG2b anti-dsDNA antibodies
were also detectable
 
. 
 
The presence of anti-dsDNA activity
Figure 1. Antipeptide antibodies in MAP–peptide-immunized mice.
BALB/c mice were immunized with 100 mg of MAP–DWEYSVWLSN
in CFA on day 0, and boosted with MAP–peptide in IFA on days 7 and
14. Control mice were immunized with MAP core in adjuvant. Sera
from the different time points were diluted 1:500, and assayed for IgG and
IgM antipeptide antibodies by ELISA. Data represent averages of five
mice receiving MAP–peptide in adjuvant and five mice receiving MAP
core in adjuvant.
Figure 2. IgG antipeptide antibodies are primarily of the IgG1 subclass.
The subclasses of the IgG antipeptide antibodies in day 149 sera from five
MAP–DWEYSVWLSN-immunized mice were measured by ELISA. 
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in MAP–peptide-immunized mice was verified by Milli-
pore filter assay. Peptide-immunized mice developed sig-
nificant dsDNA binding at day 
 
1
 
49 compared with base-
line levels, whereas no such increase was detected in MAP
core immunized mice (Fig. 7)
 
.
 
As R4A is encoded by the S107 V11 H chain gene, we
wanted to determine whether anti-dsDNA antibodies in-
duced by immunization with a R4A-selected peptide
would also be encoded by S107 VH genes. The mAb
TC54 recognizes both S107 V1 and V11 H chains, without
respect to L chain (14); therefore, we tested the anti-
dsDNA antibodies for expression of the TC54 idiotype.
TC54
 
1
 
 anti-dsDNA antibodies were present in peptide-
immunized mice, suggesting that at least some of the anti-
DNA antibodies elicited by peptide immunization express
the same VH gene family as R4A (data not shown). There-
fore, the peptide induces activation of B cells, making anti-
bodies similar to the parental R4A antibody. However, not
all the anti-DNA response is TC54 reactive, suggesting in-
volvement of other VH genes, or somatic mutation affect-
ing idiotypic specificity.
 
DWEYSVWLSN Immunization Induces Antibodies Reactive
with Other Autoantigens.
 
As antibodies against additional au-
toantigens occur commonly in systemic lupus, we studied
whether peptide-immunized BALB/c mice produced anti-
bodies against other antigens. Using Hep-2 cells as a substrate,
positive ANAs were detected in all DWEYSVWLSN-immu-
nized mice tested. The serum ANA titers ranged from 1:80
(7/10 mice) to 1:160 (3/10 mice). Pre- and postimmune
sera from mice receiving adjuvant alone, and preimmune
sera from the peptide-immunized mice, were all negative
for ANA by immunofluorescence at a dilution of 1:40 (data
not shown).
To further characterize the antigenic specificities present,
assays were performed to detect reactivity to specific nu-
clear antigens. IgG anticardiolipin and antihistone titers in-
creased in MAP–peptide-immunized mice (Fig. 8), whereas
these antibodies were not present in mice immunized with
the MAP core. To confirm that the binding to histone was
specific and not due to contaminating DNA, we repeated
the assay using DNase-treated antigen. There was no loss of
reactivity (data not shown).
To determine if the multiple antigenic specificities ob-
served in the DWEYSVWLSN-immunized mice repre-
sented antibodies cross-reactive with peptide, we per-
Figure 3. Antipeptide reactivity in MAP–peptide-immunized mice is
antigen specific. Sera from MAP–DWEYSVWLSN-immunized mice was
assayed for reactivity with DWEYSVWLSN and three additional irrele-
vant antigens (KLH, phosphorylcholine [PC], and lysozyme) by ELISA.
A significant antibody response was demonstrated only against the immu-
nizing peptide. Data represent averages of five immunized mice for each
antigen.
Figure 4. Anti-dsDNA anti-
bodies in MAP–peptide-immu-
nized mice. BALB/c mice were
immunized with 100 mg of
MAP–DWEYSVWLSN in CFA
on day 0, and boosted with
MAP–peptide in IFA on days 7
and 14. Control mice received
MAP core in adjuvant. Sera from
the different time points were di-
luted 1:500, and assayed for IgM
(left) and IgG (right) anti-dsDNA
antibodies by ELISA. Data rep-
resent averages of five mice re-
ceiving MAP–peptide and five
mice receiving MAP core. 
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formed inhibition experiments. Soluble DWEYS inhibited
 
z
 
50% of the binding of sera to dsDNA; binding to histone
was less well inhibited by peptide (Fig. 9). As the MAP
core and histone both have many lysine residues, we per-
formed inhibition assays to see if the antihistone response
cross-reacted with MAP core. MAP core alone failed to in-
hibit binding of sera to histone (data not shown).
 
Peptide-immunized Mice Develop Immunoglobulin Deposition
in the Kidney.
 
Anti-DNA antibodies have been shown to
cause lupus-like nephritis in mice (18–20). To assess if pep-
tide-induced autoantibodies were potentially pathogenic,
we assayed for renal Ig deposition in five mice on day 
 
1
 
49.
Immunized mice all had moderate Ig deposition, mostly lo-
calized to glomeruli (Fig. 10). Repeating the kidney stain-
ing with goat anti–mouse IgG1 revealed a similar pattern
and intensity of glomerular deposition, whereas the glom-
erular staining was greatly reduced or absent for IgG2a,
IgG2b, and IgG3 (data not shown). No glomerular Ig dep-
osition was present in mice immunized with MAP core
alone (Fig. 10).
 
Response to Peptide Immunization in Different Inbred Mouse
Strains.
 
To study if the breakdown in tolerance was strain
specific, we immunized several additional inbred mouse strains
[C57Bl/6 (H-2
 
b
 
), A/J (H-2
 
a
 
), AKR/J (H-2
 
k
 
), DBA/2 (H-2
 
d
 
),
and CBA/Ca (H-2
 
k
 
)] with MAP–DWEYSVWLSN using
the same protocol detailed above for BALB/c mice. No
strain mounted either an antipeptide or an anti-DNA re-
Figure 5. The titer of IgG anti-dsDNA antibodies in MAP–peptide-
immunized mice is comparable to the titer of IgG anti-dsDNA antibodies
in (NZB 3 NZW) F1 mice. Serial dilutions of day 149 sera (starting
from 1:100) from MAP–peptide-immunized mice were assayed by ELISA
for IgG anti-dsDNA antibodies. Sera from lupus-prone 6-mo-old (NZB 3
NZW) F1 mice were used for comparison. Graph depicts the average OD
at different dilutions of 10 MAP–peptide-immunized mice versus 9 (NZB 3
NZW) F1 mice.
Figure 6. IgG anti-dsDNA antibodies in MAP–peptide-immunized
mice are primarily IgG1. The subclasses of the IgG anti-dsDNA antibod-
ies in day 149 sera from five MAP–peptide-immunized mice were mea-
sured by ELISA. Controls for this assay were five sera from 6-mo-old
(NZB 3 NZW) F1 mice.
Figure 7. Anti-dsDNA antibodies in the Millipore filter assay. BALB/c
mice were immunized with 100 mg of MAP–DWEYSVWLSN in CFA
on day 0, and boosted with MAP–peptide in IFA on day 7 and day 14.
Control mice received MAP core in adjuvant. Sera from five mice in
each group at baseline (day 0) and at day 149 were diluted 1:5,000 and
incubated with radiolabeled dsDNA. The solution was filtered through a
nitrocellulose membrane, and the retained radioactivity was counted.34 Peptide Immunization Induces Autoantibody Production
sponse comparable to that induced in BALB/c (H-2d) mice
(Fig 11, bottom). Although there were some differences among
the additional mouse strains examined, even the highest re-
sponder strain had a significantly lower antibody response
to peptide and to dsDNA than BALB/c (Fig. 11, top).
Thus, only BALB/c mice demonstrated a breakdown in
tolerance when immunized with a peptide mimotope of
dsDNA.
Discussion
Although anti-dsDNA antibodies are the hallmark of the
disease systemic lupus, it has been difficult to identify an
antigen that will elicit this specificity on immunization.
DNA immunization has routinely failed to elicit anti-dsDNA
antibodies in nonautoimmune hosts (4). In an effort to find
an antigen that can induce anti-DNA reactivity, we immu-
nized BALB/c mice with a peptide surrogate for dsDNA.
We have shown that the immunization of nonautoimmune
Figure 8. MAP–peptide-immu-
nized mice have increased serum
titers of antihistone and anticar-
diolipin antibodies. Sera from
different time points after immu-
nization were diluted 1:500 and
assayed for IgG antihistone and
IgG anticardiolipin antibodies
by ELISA.
Figure 9. DWEYS inhibits binding of immunized mice sera to autoan-
tigens. Day 149 sera diluted 1:250 from four peptide-immunized mice
were incubated with serial dilutions of l-DWEYS at an initial concentra-
tion of 6.4 mM (5 mg/ml) and assayed for binding to dsDNA and his-
tone. Graph depicts the average percentage of inhibition at different pep-
tide concentrations. Peptide displays partial inhibition of binding to
dsDNA; the effect on histone binding is less.
Figure 10. Glomerular Ig deposition is present in MAP–peptide-immu-
nized BALB/c mice. Mice were killed on day 149 after the initial MAP–
DWEYSVWLSN immunization. Kidney sections were stained with
biotinylated goat anti–mouse IgG, followed by streptavidin–alkaline
phosphatase and substrate. (A, top) Representative section from a mouse
receiving MAP core. (B, bottom) Representative section from a MAP–
peptide-immunized mouse.35 Putterman and Diamond
BALB/c mice with a peptide that is bound by a pathogenic
anti-dsDNA antibody elicits anti-dsDNA and other au-
toantibodies.
Peptide libraries have been very useful in identifying
ligands for mAbs (21) when the antibody binds a protein
antigen. Yet often the ligands are not mimotopes for anti-
gen. Lundin et al. immunized mice with peptides derived
by screening random peptide libraries with a neutralizing
mAb against HIV gp120. Although immunization with
peptide led to a peptide-specific response, no reactivity
against native gp120 was detectable (22). Felici immunized
BALB/c mice with peptides derived from screening a phage
library with a neutralizing antibody against pertussis toxin.
Sera from immunized mice bound to phage bearing the
epitope and to MAP–peptide but did not recognize toxin
or neutralize its biologic activity (23). However, Westerink
et al. (24) were able to generate a protective response
against meningococcal group C infection using a peptide
mimic where the peptide was derived from the variable re-
gion of an antiidiotypic antibody. This peptide elicited pro-
tective immunity, but only after it was complexed to group
B meningococcal outer membrane proteins. Valadon et al.
screened phage peptide display libraries with 2H1, a pro-
tective antibody that binds capsular glucoronoxylomannan
(GXM) of Cryptococcus neoformans to identify peptides that
might be mimotopes for a polysaccharide antigen (25).
One consensus peptide motif reacted with several protec-
tive anti-GXM antibodies, yet immunization with this
peptide failed to elicit anti-GXM antibodies even though
there was a strong antipeptide response.
Using a phage peptide display library, we were able to
identify a peptide surrogate for dsDNA for the R4A anti-
body. Our present studies demonstrate that not only was
this peptide a mimetic of the nucleic acid, as shown previ-
ously by competitive inhibition of DNA binding to an
anti-dsDNA antibody (11), but also a mimotope that can
elicit anti-dsDNA antibody production. Importantly, mice
not only develop multiple serological autospecificities of
SLE, but also demonstrate Ig deposition in the kidney.
Thus, immunization with a peptide surrogate for dsDNA
results in a lupus-like syndrome in a nonautoimmune
mouse. We demonstrated an IgG response to dsDNA with
the highest anti-dsDNA titers to be IgG1. This suggests a
TH2-related mechanism for induction of autoantibodies.
Further experiments are underway to confirm T cell in-
volvement in the autoantibody response and to characterize
the responding T cells.
Peptide-immunized BALB/c mice produce multiple au-
toantibodies. Inhibition studies with soluble peptide dem-
onstrate that antibodies induced by peptide immunization
are broadly cross-reactive, as dsDNA and histone reactivity
can be partially inhibited by peptide. It has been reported
that anti-DNA antibodies that bind chromatin may be in-
hibited by DNA or histone (26, 27) suggesting the exist-
ence of common antigenic epitopes on these autoantigens.
However, not all the reactivity to these autospecificities is
peptide inhibitable. There are several mechanisms that
could account for the generation of autoreactive B cells
that do not react with the immunizing peptide. Some B
cells may initially be specific for peptide, and then acquire
Figure 11. (Left) Antipeptide
response in nonautoimmune
mouse strains. Groups of mice
from the BALB/c (five mice),
AKR/J (five mice), A/J (three
mice), C57B1/6 (five mice),
DBA/2 (five mice), and CBA
(five mice) strains were immu-
nized with MAP–peptide as de-
scribed, and sera were diluted
1:500. The ELISA was devel-
oped with an anti-IgG antibody.
Although some differences in the
magnitude of the antipeptide re-
sponse between these strains are
evident, even the highest re-
sponder in this group has a mark-
edly lower response than BALB/c
mice. (Right) Anti-dsDNA au-
toantibody response in nonauto-
immune mouse strains. Sera
were diluted 1:500, and the
ELISA was performed as de-
scribed. The anti-DNA antibody
response in BALB/c mice was
higher than in any other strain.36 Peptide Immunization Induces Autoantibody Production
novel autospecificities or lose peptide specificity through
somatic mutation. Previous studies from this laboratory
(28, 29) have shown that anti-dsDNA B cells can be gener-
ated by somatic mutation of antiphosphorylcholine anti-
bodies arising during an in vivo response. If this mechanism
is operative in our model, by studying genealogies of mAb
from peptide-immunized mice we would expect to find
cross-reactive B cells (those reacting with both peptide and
dsDNA) as well as sibling B cells in which mutation has led
to the loss of reactivity with peptide while maintaining re-
activity with autoantigen. A second mechanism to explain
the generation of novel autoantibody specificities might be
B cell antigen presentation and epitope spreading. Re-
cently, James et al. (30) demonstrated that rabbits immu-
nized with a Sm B/B9–derived octapeptide develop anti-
bodies that not only bind this peptide, but also bind to
many other Sm B/B9 peptides; subsequently, these rabbits
develop antibodies that bind to other splicesosomal pro-
teins (Sm D, RNP 70K, A, C). Similarly, rabbits immu-
nized with short peptides from the 60-kD Ro particle de-
velop an autoimmune response to the entire 60-kD Ro
antigen (31). Four of the nine rabbits also developed anti-
La reactivity, while two of the nine rabbits were found to
have anti-dsDNA antibodies. Other studies have also dem-
onstrated that immunization with peptides derived from
known self-protein molecules (Ro, and La) can lead to in-
tra- and intermolecular epitope spreading of the immune
response to molecules that exist in vivo as multimolecular
complexes (32). A third possible mechanism for generation
of the multiple specificities involves the idiotypic network.
Antiidiotypic antibodies to antibodies generated in the an-
tipeptide immune response might induce production of an-
tibodies that bear a shared idiotype but lack any specificity
for the immunizing peptide. Some of these might bind self-
antigens. Although this mechanism has been hypothesized
in both human and murine lupus (33), evidence remains
inconclusive.
One unanticipated result of this study was the finding
that only BALB/c mice developed an antipeptide response
and significant autoimmunity after peptide immunization.
That little to no antipeptide response was elicited in five
other mouse strains raises two possibilities. First, given the
strains studied, we may be observing an Ir gene effect in the
response to the immunizing peptide. It is possible that class
II molecules of the d haplotype are necessary for peptide
presentation (34). Class II genes are often important sus-
ceptibility factors for autoimmune disease (35, 36). Studies
are underway in other strains, including congenic strains, to
address this question. However, preliminary studies suggest
that Ir genes do not control this response, as DBA/2 (H-2d)
mice do not mount an antipeptide or an anti-DNA re-
sponse. A similar finding was reported recently by James
and Harley (37), showing a non–H-2–dependent, strain-
specific response to an Sm-derived peptide in mice. Alter-
natively, it may be that peptide induces few antibodies that
do not cross-react with DNA or another self-specificity.
The BALB/c genetic background may predispose these
mice to a breakdown of self-tolerance. In strains that main-
tain self-tolerance, no antipeptide response can be induced.
The genetic factors that might cause BALB/c mice to be
susceptible to breaking self-tolerance in this model are not
known. However, it is known that thresholds for maintain-
ing self-tolerance differ in different strains of mice, and are
determined by the interplay of many genes. For example,
homozygosity for the lpr defect on a C57Bl/6 genetic
background results in a greatly attenuated phenotype, rela-
tive to the same gene defect on the MRL background (38).
Similarly, the bc1-2 transgene expressed in the B cell lin-
eage causes autoantibody production in some strains but
not others (39). Further studies will allow us to dissect the
full complement of genetic determinants responsible for the
autoimmune response to the DWEYSVWLSN peptide.
Immunization of nonautoimmune mice with unmodi-
fied mammalian or bacterial dsDNA does not lead to the
production of high affinity IgG anti-DNA antibodies that
bind eukaryotic DNA. The elicited antibodies are specific
for bacterial DNA and so are dissimilar to the anti-DNA
antibodies found in lupus (5, 6). In recent years, it has been
reported that DNA may become more immunogenic
when complexed to various DNA-binding proteins. In
these models, a foreign protein functions as a carrier and
DNA as a hapten. For example, immunization of nonauto-
immune BALB/c mice with dsDNA complexed with
DNase I elicited IgG anti-dsDNA antibodies in about one
third of immunized mice, whereas no such antibodies were
generated by DNA immunization alone (40). Rekvig et al.
(42) found that mice given polyoma BK virus developed
anti-dsDNA and antihistone antibodies. This autoantibody
response could be replicated by immunization with the in-
tact polyoma BK virus large T antigen, a DNA-binding
protein. In this model, a single induced mutation in T anti-
gen that resulted in loss of its DNA-binding property al-
most completely abrogated the anti-DNA response to im-
munization (41, 42). This suggests that the anti-DNA
response was dependent on the DNA-binding property of
T antigen. Similarly, Marion et al. (43) have described in-
duction of anti-dsDNA antibodies by complexes of DNA
and a DNA-binding protein, the Fus 1 peptide derived
from Trypanosoma cruzi. The conclusion from all of these
studies is that DNA complexed to a DNA-binding protein
has immunogenic potential in several nonautoimmune
models, whereas eukaryotic DNA alone is relatively non-
immunogenic.
In all of these models, a DNA-binding protein that func-
tions as a carrier protein is required to be recognized by T
cells, and to help elicit the B cell response to dsDNA.
These studies, as well as studies by Pisetsky and coworkers
(5, 6, 44) addressing immunogenicity of bacterial DNA, fo-
cus on DNA as a crucial eliciting antigen for B cells in the
autoimmune process in SLE. In the model reported here,
peptide is a DNA surrogate, not a DNA-binding protein.
Thus, in this model, anti-DNA antibodies are elicited di-
rectly by a protein antigen, demonstrating that nucleic acid
is not essential for driving production of anti-DNA anti-37 Putterman and Diamond
bodies, and that a protein that mimics DNA as an antigen is
sufficient to generate autoantibody production in nonauto-
immune animals. We would like to suggest that the trig-
gering antigen in SLE could be a protein antigen without
DNA-binding properties, and that the search for triggering
antigens in SLE must be significantly expanded.
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